Treats clinically important hypotension occurring in the setting of anesthesia. ANDA 216129, held by Mankind Pharma. Ephedrine Sulfate.
As of Nov 16, 2026, ANDA 216129 (Ephedrine Sulfate), held by Mankind Pharma, was first approved by FDA on Apr 14, 2022, with 0 approved supplements and 0 published complete response letters.
Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 14, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ephedrine Sulfate50MG/ML (50MG/ML) · solution;intravenous | Ephedrine Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters